QIAGEN Added to Russell 1000 and Russell 3000 Indexes

VENLO, The Netherlands, June 28, 2011 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that its common shares were added to the U.S. large-cap Russell 1000 Index and the broad-market Russell 3000 Index. This change came into effect when Russell Investments reconstituted its equity indexes after the close of markets on June 24, 2011. The Russell indexes are widely used by participants in the capital markets, including index funds and as portfolio benchmarks for investment strategies.

"We are pleased that QIAGEN's common shares have been included in the Russell indexes. This inclusion provides further support and liquidity for QIAGEN's common shares, and thereby more benefits to participating in QIAGEN's growth and creation of value for shareholders," said Peer M. Schatz, CEO of QIAGEN.

QIAGEN common shares have traded on The NASDAQ Stock Market since the Company's initial public offering on June 28, 1996, and on the Prime Standard Segment of the Frankfurt Stock Exchange since January 1, 2003.

About QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between business segments, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Contacts:

Investor Relations        
John Gilardi             +49-2103-29-11711  
Dr. Solveigh Mähler      +49-2103-29-11710    
Albert F. Fleury         +1-301-944-7028        
e-mail: [email protected]

Public Relations    
Dr. Thomas Theuringer    +49-2103-29-11826
e-mail: [email protected]    +1-240-686-7425

SOURCE Qiagen N V